Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. (Nasdaq: ALT) is a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapeutics and vaccines addressing critical public health and biodefense needs. Leveraging the unique properties of its proprietary platform technologies, Altimmune is adept at swiftly designing product candidates targeting a range of diseases, including respiratory conditions, chronic infections, and cancer.
Altimmune's advanced Densigen™ T-cell platform technology is specifically designed to guide the immune system's response against complex disease targets by focusing on multiple antigens simultaneously. Another key platform, RespirVec™, uses needle-free intranasal delivery for faster and broader immunity against pathogens compared to traditional vaccines.
The company is also heavily involved in addressing obesity and liver diseases through its innovative peptide therapeutics. The lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist under development for obesity and non-alcoholic steatohepatitis (NASH). Pemvidutide has shown promising results in clinical trials, achieving significant weight loss and liver fat reduction. It has received Fast Track designation from the U.S. FDA for treating NASH, highlighting its potential to meet significant unmet medical needs.
Altimmune's pipeline also includes HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. However, the company has recently decided to cease further development on HepTcell based on Phase 2 trial findings.
Financially, Altimmune maintains a robust cash position, enabling it to advance its clinical programs. Recent financial results indicate a focused investment in research and development, ensuring continued progress in its pipeline.
Significant recent achievements include:
- Positive top-line results from the 48-week MOMENTUM Phase 2 obesity trial of pemvidutide.
- Ongoing Phase 2b IMPACT trial of pemvidutide in MASH with top-line results expected in Q1 2025.
- Strong financial position with substantial cash reserves to support ongoing and future research activities.
Altimmune is poised at the forefront of developing transformative therapies for serious health conditions, potentially delivering significant advancements in patient care.
Altimmune, Inc. announced that Dr. Stephen A. Harrison will present results from the 12-week Phase 1b and subsequent extension trials of pemvidutide for non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference on January 7, 2023. Pemvidutide, a dual receptor agonist for obesity and NASH, showed significant reductions in liver fat and body weight. The company is focused on the development of innovative therapeutic solutions targeting liver diseases and obesity, with pemvidutide being a key candidate.
Altimmune has reported positive topline results from a 24-week trial of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD). At doses of 1.8 mg and 2.4 mg, participants achieved significant reductions in liver fat content, with over 75% relative decrease observed. The trial also reported notable declines in serum alanine aminotransferase and improved glycemic control. Weight loss averages reached 7.2% for non-diabetic subjects. Pemvidutide showed a favorable safety profile, with mostly mild adverse events. The results suggest potential for advancement to Phase 2b trials for NAFLD.
Altimmune, a clinical-stage biopharmaceutical company (Nasdaq: ALT), will participate in two upcoming investor conferences. The first is the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 29, 2022, featuring a fireside chat at 10:55 am ET. The second is the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, with a fireside chat at 10:00 am ET. Both sessions will be accessible via webcast on Altimmune's website. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with notable products like pemvidutide (ALT-801).
Altimmune, Inc. (Nasdaq: ALT) reported its financial results for Q3 2022, revealing a net loss of $23.5 million, or $0.48 per share, an improvement from a $33.5 million loss in Q3 2021. The company holds $201.9 million in cash and equivalents as of September 30, 2022. Key upcoming milestones include topline data from a 24-week Phase 1b NAFLD trial expected in mid-December 2022 and interim results from the MOMENTUM Phase 2 obesity trial anticipated in Q1 2023. The company aims to leverage significant reductions in liver fat and body weight from its pemvidutide program.
Altimmune, Inc. (Nasdaq: ALT) will report its Q3 2022 financial results on November 10, 2022, followed by a management conference call at 8:30 am ET. The discussion will focus on financial performance and business updates. Live streaming of the call will be available on the company's Investor Relations website. Altimmune specializes in peptide-based therapeutics for obesity and liver diseases, with its lead candidate being pemvidutide, aimed at treating obesity and non-alcoholic steatohepatitis (NASH).
Altimmune, Inc. (Nasdaq: ALT) announced its upcoming scientific presentations at two conferences in November 2022. The first presentation, at the American Heart Association Scientific Sessions on November 5, will focus on the effects of Pemvidutide (ALT-801) on lipid mediators. The second, at the American Association for the Study of Liver Disease on November 7, will present results from a Phase 1b trial evaluating a dual receptor agonist's impact on liver fat reduction in patients with non-alcoholic fatty liver disease. Presentation materials will be accessible on Altimmune's website.
Altimmune, Inc. (Nasdaq: ALT) announced the successful completion of patient dosing for its Phase 2 MOMENTUM trial, evaluating the efficacy and safety of pemvidutide, a dual receptor agonist for obesity and NASH. This multicenter trial involves 320 subjects randomized to receive various doses of pemvidutide or placebo over 48 weeks, focusing on weight change and metabolic profiles. The trial's 24-week interim analysis is anticipated in Q1 2023, marking a significant milestone in pemvidutide's development.
Altimmune, Inc. (ALT) announced positive results from a 12-week Phase 1b study of pemvidutide for non-alcoholic fatty liver disease (NAFLD). All dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved primary endpoints, with a 68.5% relative reduction in liver fat at the 1.8 mg dose. Subjects without diabetes saw a mean weight loss of 4.9% (placebo-adjusted 4.7%). The treatment was well-tolerated, mainly with mild gastrointestinal events, and no serious adverse events were reported. Next steps include data from a 24-week NAFLD trial and interim results from the MOMENTUM obesity trial.
Altimmune, Inc. (Nasdaq: ALT) reported its financial results for the second quarter of 2022, with a net loss of $20.1 million or $0.42 per share, an improvement from a net loss of $24.8 million in Q2 2021. The company reported minimal revenue due to the discontinuation of T-COVID and NasoShield programs. Altimmune is advancing its pemvidutide clinical trials, with topline data from a 12-week Phase 1b trial in subjects with obesity/overweight and non-alcoholic fatty liver disease (NAFLD) expected in mid-September 2022.
Research and development expenses increased to $16 million, primarily due to pemvidutide development.
Altimmune, Inc. (Nasdaq: ALT) will announce its second quarter 2022 financial results on August 11, 2022, followed by a conference call at 8:30 am E.T. to discuss these results and provide a business update. The call will be accessible via webcast on Altimmune's Investor Relations website. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with its lead candidate, pemvidutide, targeting obesity and NASH. Altimmune is also advancing its HepTcell™ immunotherapeutic for chronic hepatitis B.
FAQ
What is the current stock price of Altimmune (ALT)?
What is the market cap of Altimmune (ALT)?
What does Altimmune, Inc. specialize in?
What are the main products in Altimmune's pipeline?
What is pemvidutide?
Has pemvidutide received any regulatory designations?
What is Densigen™ platform technology?
How does the RespirVec™ platform work?
What recent financial results has Altimmune reported?
What are the current clinical trials for pemvidutide?
What is the status of HepTcell™ development?
Where can I find more information about Altimmune?
